Ra Capital Management, L.P. Eliem Therapeutics, Inc. Transaction History
Ra Capital Management, L.P.
- $6.17 Billion
- Q4 2024
A detailed history of Ra Capital Management, L.P. transactions in Eliem Therapeutics, Inc. stock. As of the latest transaction made, Ra Capital Management, L.P. holds 31,419,267 shares of ELYM stock, worth $129 Million. This represents 2.09% of its overall portfolio holdings.
Number of Shares
31,419,267
Previous 31,419,267
-0.0%
Holding current value
$129 Million
Previous $160 Million
19.25%
% of portfolio
2.09%
Previous 2.23%
Shares
3 transactions
Others Institutions Holding ELYM
# of Institutions
76Shares Held
51MCall Options Held
0Put Options Held
0-
Janus Henderson Group PLC London, X03.18MShares$13.1 Million0.01% of portfolio
-
Samsara Bio Capital, LLC Palo Alto, CA2.61MShares$10.7 Million3.29% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$6.19 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT1.04MShares$4.27 Million0.19% of portfolio
-
Bank Of America Corp Charlotte, NC1.03MShares$4.25 Million0.0% of portfolio
About Eliem Therapeutics, Inc.
- Ticker ELYM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,567,700
- Market Cap $109M
- Description
- Eliem Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 for chronic pain, which is in Phase II...